SWEDISH MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $54.2M
- Transactions
- 5,057
- Companies
- 40
- Average per transaction
- $10,708
Who reported the payments
| Amgen | $6,205,703 |
| Gilead | $5,744,026 |
| AstraZeneca | $5,318,419 |
| Eli Lilly | $4,674,869 |
| Bristol Myers Squibb | $4,489,012 |
| E.r. Squibb & Sons, L.L.C. | $2,487,843 |
| Medtronic | $2,395,095 |
| AbbVie | $2,065,437 |
| Regeneron | $2,048,581 |
| Merck | $1,607,117 |
| Edwards Lifesciences | $1,218,988 |
| Seagen Inc. | $1,058,908 |
| Genentech, Inc. | $1,055,444 |
| Abbott | $911,416 |
| Intercept Pharmaceuticals, Inc. | $907,703 |
| Acerta Pharma LLC | $905,031 |
| Pfizer | $780,198 |
| Biogen | $744,644 |
| Pharmacyclics LLC, An Abbvie Company | $708,588 |
| Novartis | $621,160 |
| Fujifilm Healthcare Americas Corporation | $607,839 |
| Takeda Pharmaceuticals U.S.A., Inc. | $477,985 |
| TG Therapeutics, Inc. | $369,848 |
| F. Hoffmann-la Roche AG | $367,245 |
| Boston Scientific | $346,543 |
| Sanofi | $294,445 |
| Clovis Oncology, Inc. | $268,108 |
| Stryker | $254,879 |
| Nevro Corp. | $252,255 |
| Epizyme, Inc. | $250,725 |
| Trillium Therapeutics USA, LLC | $233,543 |
| UCB SA | $225,977 |
| Alkermes, Inc. | $225,214 |
| Adaptive Biotechnologies Corporation | $193,200 |
| Johnson & Johnson | $184,852 |
| Insightec,ltd | $167,320 |
| Tesaro, Inc. | $164,342 |
| Balt USA, LLC | $158,760 |
| Histosonics, Inc. | $156,551 |
| Boehringer Ingelheim | $137,800 |